167 related articles for article (PubMed ID: 9673037)
1. [Occurrence of myelofibrosis in individual types of chronic myeloproliferative diseases].
Adamkov M; Plank L; Szépe P
Bratisl Lek Listy; 1998 May; 99(5):240-4. PubMed ID: 9673037
[TBL] [Abstract][Full Text] [Related]
2. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification.
Buhr T; Georgii A; Choritz H
Pathol Res Pract; 1993 Mar; 189(2):121-32. PubMed ID: 8321741
[TBL] [Abstract][Full Text] [Related]
3. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
4. Fibrosis identified in the bone marrow biopsies of patients with essential thrombocythemia: its incidence and significance for the differential diagnostic considerations.
Marcinek J; Plank L; Szépe P; Balhárek T
Cesk Patol; 2008 Jul; 44(3):62-6. PubMed ID: 18783136
[TBL] [Abstract][Full Text] [Related]
5. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
Thiele J; Kvasnicka HM
Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
[TBL] [Abstract][Full Text] [Related]
6. Karyotype findings and molecular analysis of the bcr gene rearrangement supplementing the histologic classification of chronic myeloproliferative disorders.
Werner M; Nolte M; Kaloutsi V; Buhr T; Kausche F; Georgii A
Lab Invest; 1995 Apr; 72(4):405-10. PubMed ID: 7723278
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.
Méhes G; Tzankov A; Hebeda K; Anagnostopoulos I; Krenács L; Bedekovics J
Histopathology; 2015 Nov; 67(5):617-24. PubMed ID: 25825163
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
Rudzki Z; Papla B; Stachura J
Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
[TBL] [Abstract][Full Text] [Related]
9. [Histomorphologic findings of the bone marrow in chronic myeloproliferative diseases].
Thiele J; Fischer R
Z Hautkr; 1989 Oct; 64(10):903-4, 909-12. PubMed ID: 2686247
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloproliferative disorders (CMPD).
Burkhardt R; Bartl R; Jäger K; Frisch B; Kettner G; Mahl G; Sund M
Pathol Res Pract; 1984 Nov; 179(2):131-86. PubMed ID: 6395125
[TBL] [Abstract][Full Text] [Related]
11. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD).
Bartl R; Frisch B; Wilmanns W
Eur J Haematol; 1993 Jan; 50(1):41-52. PubMed ID: 8436214
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity.
Lundberg LG; Lerner R; Sundelin P; Rogers R; Folkman J; Palmblad J
Am J Pathol; 2000 Jul; 157(1):15-9. PubMed ID: 10880370
[TBL] [Abstract][Full Text] [Related]
14. Follow-up studies with sequential bone marrow biopsies in chronic myeloid leukaemia and so-called primary (idiopathic) osteo-myelofibrosis. Evolution of histopathological lesions and clinical course in 40 patients.
Thiele J; Simon KG; Fischer R; Zankovich R
Pathol Res Pract; 1988 Aug; 183(4):434-45. PubMed ID: 3186544
[TBL] [Abstract][Full Text] [Related]
15. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
16. Inability of immunomorphometric assessment of angiogenesis to distinguish primary versus secondary myelofibrosis.
Sharma P; Pati HP; Mishra PC; Dinda AK; Gupta R; Sharma A; Jacob TG
Anal Quant Cytol Histol; 2011 Aug; 33(4):236-44. PubMed ID: 21980629
[TBL] [Abstract][Full Text] [Related]
17. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.
Georgii A; Buhr T; Buesche G; Kreft A; Choritz H
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():15-29. PubMed ID: 8951769
[TBL] [Abstract][Full Text] [Related]
18. Myelofibrosis in chronic myeloproliferative disorders--dynamics and clinical impact.
Thiele J; Kvasnicka HM
Histol Histopathol; 2006 Dec; 21(12):1367-78. PubMed ID: 16977587
[TBL] [Abstract][Full Text] [Related]
19. [Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases].
Nafe R; Holgado de Colombo S; Choritz H; Georgii A
Pathologe; 1995 Jan; 16(1):34-40. PubMed ID: 7886012
[TBL] [Abstract][Full Text] [Related]
20. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
